1. Home
  2. AVDL vs MLYS Comparison

AVDL vs MLYS Comparison

Compare AVDL & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • MLYS
  • Stock Information
  • Founded
  • AVDL 2015
  • MLYS 2019
  • Country
  • AVDL Ireland
  • MLYS United States
  • Employees
  • AVDL N/A
  • MLYS N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVDL Health Care
  • MLYS Health Care
  • Exchange
  • AVDL Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • AVDL 786.3M
  • MLYS 634.6M
  • IPO Year
  • AVDL 1996
  • MLYS 2023
  • Fundamental
  • Price
  • AVDL $7.64
  • MLYS $9.86
  • Analyst Decision
  • AVDL Strong Buy
  • MLYS Strong Buy
  • Analyst Count
  • AVDL 6
  • MLYS 2
  • Target Price
  • AVDL $20.00
  • MLYS $30.00
  • AVG Volume (30 Days)
  • AVDL 1.7M
  • MLYS 241.2K
  • Earning Date
  • AVDL 03-03-2025
  • MLYS 03-20-2025
  • Dividend Yield
  • AVDL N/A
  • MLYS N/A
  • EPS Growth
  • AVDL N/A
  • MLYS N/A
  • EPS
  • AVDL N/A
  • MLYS N/A
  • Revenue
  • AVDL $138,160,000.00
  • MLYS N/A
  • Revenue This Year
  • AVDL $515.63
  • MLYS N/A
  • Revenue Next Year
  • AVDL $49.32
  • MLYS N/A
  • P/E Ratio
  • AVDL N/A
  • MLYS N/A
  • Revenue Growth
  • AVDL 1523.50
  • MLYS N/A
  • 52 Week Low
  • AVDL $7.39
  • MLYS $8.58
  • 52 Week High
  • AVDL $19.09
  • MLYS $16.91
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 30.42
  • MLYS 39.40
  • Support Level
  • AVDL $7.40
  • MLYS $9.57
  • Resistance Level
  • AVDL $8.01
  • MLYS $10.71
  • Average True Range (ATR)
  • AVDL 0.44
  • MLYS 0.84
  • MACD
  • AVDL -0.07
  • MLYS 0.00
  • Stochastic Oscillator
  • AVDL 6.93
  • MLYS 26.42

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking three or more antihypertensive medications typically including a diuretic.

Share on Social Networks: